The significant equity issuance at a market cap of only $2 million suggests severe dilution for existing shareholders. Traders should monitor how the market prices this dilution against the potential value of the SAB-142 clinical program, particularly as the company advances its Phase 2b trial for type 1 diabetes.
Price Chart
Executive Summary
SAB Biotherapeutics is conducting a public offering of 19.3 million shares of common stock and pre-funded warrants to purchase up to 2.8 million shares at $3.85 per share, with an option for underwriters to purchase up to an additional 3.3 million shares. The company expects to raise approximately $69.7 million in net proceeds (up to $81.7 million if the option is exercised), which will be used primarily to fund clinical development of its lead product candidate SAB-142 for type 1 diabetes.
Key Financial Metrics
Key Facts
- Offering includes 19,324,677 shares of common stock and pre-funded warrants for 2,753,246 shares at $3.85 per share
- Underwriters have a 30-day option to purchase up to 3,311,688 additional shares
- Expected net proceeds of $69.7 million ($81.7 million if option exercised), after underwriting discounts and expenses
- Proceeds will be used to fund development of SAB-142 through clinical trials, manufacturing, regulatory activities, and general corporate purposes
- Company has a market cap of only $2 million despite raising significant capital
Financial Impact
Approximately $69.7 million in net proceeds ($81.7 million maximum) through issuance of 22.1 million shares (up to 25.4 million with option) and warrants for 2.8 million shares
Risk Factors
- Extreme shareholder dilution from issuing over 22 million new shares
- Low market cap of $2 million indicates limited market confidence despite capital raise
- Clinical-stage biotech with unproven technology and no commercial products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-114730 |
| Document: sabs-ex4_1.htm | 0001193125-26-114730 |
| Document: sabs-20260317.htm | 0001193125-26-114730 |
| Document: sabs-ex5_1.htm | 0001193125-26-114730 |
| Document: sabs-ex99_2.htm | 0001193125-26-114730 |
| Document: sabs-ex99_1.htm | 0001193125-26-114730 |
| Document: 0001193125-26-114730-index-headers.html | 0001193125-26-114730 |
| Document: 0001193125-26-114730-index.html | 0001193125-26-114730 |
| Document: 0001193125-26-114730.txt | 0001193125-26-114730 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 7, 2026 12w ago | 8-K | $3.90 $3.17 | ▼ −18.72% | ▼ −20.71% | $3.01 (−22.95%) |
May 29, 2026 18w ago | Press Release | $3.60 $3.62 | ▲ +0.56% | ▼ −0.63% | $3.01 (−16.53%) |
May 12, 2026 20w ago | Press Release | $3.62 $3.85 | ▼ −6.35% | ▼ −1.97% | $3.01 (+16.99%) |
Mar 19, 2026 28w ago | Press Release | $3.75 $3.90 | ▲ +4.00% | ▼ −10.42% | $3.01 (−19.87%) |
Mar 19, 2026 28w ago | 8-K | $3.78 $3.90 | ▼ −3.17% | ▲ +11.17% | $3.01 (+20.50%) |
Mar 18, 2026 28w ago | Press Release | $3.70 $3.38 | ▲ +8.65% | ▲ +20.17% | $3.01 (+18.78%) |
Mar 17, 2026 28w ago | Press Release | $3.70 $3.38 | ▲ +8.65% | ▲ +20.17% | $3.01 (+18.78%) |
Mar 10, 2026 29w ago | Press Release | $4.10 $3.36 | ▼ −18.05% | ▼ −29.73% | $3.01 (−26.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access